Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-PD-1 antibody plus R-CHOP for untreated CD5-positive diffuse large B-cell lymphoma
ChiCTR2300072920Phase 4Recruiting
- Sponsor
- Sir Run-Run Shaw Hospital
- Start
- Jan 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone in diffuse large B-cell lymphoma (DLBCL), sponsored by Sir Run-Run Shaw Hospital. Primary endpoints: overall response rate, overall survival and 1 more. Started Jan 2021; status: recruiting.
02
Drugs
rituximabcyclophosphamidedoxorubicinvincristineprednisone
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ChiCTR2300072920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300072920.